Omada Health Inc

Omada Health maintains a strong liquidity position with $222.0 million in cash and equivalents, representing 72.4% of total assets, and a current ratio of 3.6, well above the industry median of 1.8. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. However, free cash flow of -$16.4 million and operating cash flow of $18.3 million suggest ongoing reinvestment in operations despite positive cash generation. Profitability metrics show mixed performance. The company reported a net loss of $12.8 million and an operating loss of $14.1 million, with a return on equity of -5.56% and return on assets of -4.18%. These figures fall below the industry median ROE of 12.3% and ROA of 6.8%, indicating underperformance relative to peers. Gross profit of $171 million on $260 million in revenue yields a 65.7% margin, which is in line with the industry median of 64.2%. Geographically, Omada Health's revenue is concentrated in the United States, with no material international operations disclosed. The company operates in a single business segment focused on digital therapeutics, with no diversification across product lines or geographic regions. This concentration increases exposure to U.S. healthcare policy shifts and reimbursement dynamics. The company's growth trajectory is modest, with no revenue history provided for prior periods. Analysts project a mean price target of $21.00, implying 28.3% upside from the current market price of $16.44. However, the absence of strong-buy ratings and a mean recommendation of 2.17 (Buy) suggests cautious optimism among analysts. The company's free cash flow and operating cash flow indicate limited capacity for organic growth without external financing. Risk factors include the company's negative net income and operating income, which could pressure liquidity if cash burn accelerates. The risk assessment indicates low dilution potential, with no immediate filing-based flags detected. However, the absence of long-term debt does not eliminate the possibility of future equity issuance to fund growth or R&D. Recent events include the publication of analyst price targets and recommendations, with 10 Buy ratings and 2 Hold ratings. No material filings or transcripts were disclosed in the provided data. The company's digital therapeutics model is subject to regulatory scrutiny and reimbursement challenges, which could impact future revenue streams.